Key result
Mutant β2-adrenoreceptor G allele linked to ~75% higher risk of hospitalization or death versus wild-type.
Why the study?
Does the Gln27Glu polymorphism of the β2-adrenergic receptor gene affect the long-term prognosis in patients with heart failure?
Cohort (n=200)
Does the Gln27Glu polymorphism of the β2-adrenergic receptor gene affect the long-term prognosis in patients with heart failure?
The Gln27Glu polymorphism of the β2-adrenergic receptor gene is associated with a higher risk of atrial fibrillation and hospitalization in patients with heart failure.
Answers are grounded in this paper and cite their sources.
Gln27Glu polymorphism may identify higher-risk HF patients; leaves open whether genotyping improves prognosis or warrants trials.
The aim: to determine the influence of Gln27Glu polymorphism of the β2-adrenergic receptor gene on the long-term prognosis of patients with heart failure.Material and methods. The study included 200 patients with heart failure. The clinical course of the disease was evaluated and a genetic study of Gln27Glu polymorphism of the β2-adrenergic receptor gene was done. The material for molecular-genetic research was peripheral blood leukocytes of patients. Isolation of genomic DNA from blood leukocytes for molecular genetic studies was carried out using a commercial "DNA-sorb-B" kit in accordance with the instruction for the kit. Primer sequences were used for the polymerase chain reaction.Results. An analysis of the distribution of genotypes of the polymorphic Gln27Glu locus of the β2-adrenoreceptor gene in patients with heart failure showed that the genotype Gln27Gln occurs in 33 % of cases; Glu27Glu – in 13 %; Gln27Glu – in 54 %. Carriers of the mutant allele (G) of the β2-adrenoreceptor gene have a high incidence of atrial fibrillation (35.6 % vs. 7.7 %) over 3 years of follow-up. Hospitalization (42.0 % versus 19.2 %) and the frequency of reaching the combined end point (hospitalization + death) (54.0 % vs. 30.8 %) are greater among patients who carry the mutated G allele compared to homozygous patients with the "wild" allele C, for 3 years of observation. Polymorphism of the Gln27Glu gene of the β2-adrenoreceptor does not significantly affect the three-year mortality of patients with heart failure.Conclusions. The carriers of the mutant allele (G) of β2-adrenergic receptors have a high incidence of atrial fibrillation, hospitalization and the achievement of a combined end point (hospitalization + death) for 3 years of observation, compared to homozygous patients with the "wild-type" allele C. The polymorphism of the gene Gln27Glu of the β2-adrenoceptors does not affect the three-year mortality of patients with heart failure
No takes yet. Share an insight, caveat, or question.
Pyvovar et al. (2018) conducted a cohort in heart failure (n=200). Mutant allele (G) of the β2-adrenoreceptor gene vs. Homozygous 'wild' allele C was evaluated on combined end point (hospitalization + death). Carriers of the mutant G allele of the β2-adrenoreceptor gene had a higher 3-year incidence of hospitalization or death compared to wild-type C allele carriers.
Synapse has enriched 10 related papers. Consider them for comparative context: